EN NEV (AP) – The United Nations health agency says its global distribution of coronavirus vaccines is not affecting even as a growing number of countries, especially Europe, stopped using the AstraZeneca vaccine on Monday due to blood-borne mucosal concerns.
The World Health Organization says AstraZeneca vaccines for its COVAX program, which delivers the vaccines mainly to low- and middle-income countries, are made in India and South Korea, with suspensions ordered in batches made in Europe.
“We understand that these are precautionary measures,” said Mariangela Simao, WTO Assistant Director-General. “I would like to say this from countries in other European regions. “Until now, the vaccines (in question) are of European production, not vaccines provided through the COVAX facility.”
Starting last week, Denmark, Germany, France, Italy and Spain joined the growing list of mainly European countries that have temporarily stopped using the AstraZeneca vaccine in recent days to investigate cases of post-vaccination blood clots. Others include Thailand and Congo.
“This does not mean that these events are related to vaccinations,” WHO Director-General Tedros Adanom Hebrais told a news conference. “But studying them is a common practice, it shows that the control system works, effective controls work.”
While AstraZeneca is just one of several vaccines available in Europe, the vaccine still plays a huge role in COVAX. Began began shipping in late February and plans to ship more than 200 million doses by the end of May, almost all of which are versions of the Oxford-AstraZeneca vaccine.
A total of 92 countries are required to receive free vaccines through COVAX, which is administered by the WHO. Gavi, a group of vaccines; ից Coalition of Epidemiological Preparation Innovations. Another 90 countries and eight regions have agreed to pay for doses through the program.
WHO Chief Scientist Dr. Sumya Swaminathan said that 300 million doses of coronavirus vaccines had been injected worldwide, with no documented deaths in any of them.
He said the rate of blood clots in people who received the AstraZeneca vaccine was “actually lower than you would expect in the general population.”
In India, where large doses of AstraZeneca COVAX are produced, the Indian Press Trust reported 234 “adverse events”, including 71 deaths, on Friday among people taking the AstraZeneca vaccine or another dose. received by Bharat, India. Biotechnology
The Indian government is reviewing the cases. Activists and medical ethics experts are concerned about the effectiveness of mechanisms to control adverse events in India.
The WHO says its current proposal is that the benefits of fighting AstraZeneca’s COVID-19 vaccine, which has killed more than 2.6 million people worldwide, far outweigh the risks.
AP Science writer Anirudda Gossal contributed to this New Delhi report.
Follow the AP epidemic coverage: